Signal Analysts put Spravato global sales at $2 billion in 2025
Summary
The Initiative cites unnamed analysts projecting that Johnson & Johnson's intranasal esketamine therapy Spravato would reach two billion dollars in global sales in 2025. GWI presents this as the commercial precedent for reimbursable, FDA-designated psychedelic-adjacent medicines.
Classification
Main topicIndustry & Supply Chains
Region menusGlobal
Occurrencescope:global
Impactscope:global
Time horizon0-3 years (2026-07-26)
Last updated2026-07-29 04:49:52
Evidence 1
- Initiative Trends 2026: Collective Intelligence and Foresight from Global Wellness Leaders Global Wellness Institute page=82;section=Psychedelics and Healing Initiative Trends / TREND 1: YAY FOR THE FDA 2026-05 accessed 2026-07-26
Part of trends 1
Directly linked issues 0
No objects.
Relation types: supports
Public id: fm-d6bcf1ac2f80